| Overview |
| bs-10021R-PE-Cy7 |
| NLRP3 Polyclonal Antibody, PE-Cy7 Conjugated |
| WB, FCM |
| Human, Mouse, Rat, Dog |
| Specifications |
| PE-Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NLRP3 |
| 15-120/1036 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 114548 |
| Q96P20 |
| Cytoplasm, Nucleus, Secreted |
| NACHT, LRR and PYD domains-containing protein 3; Angiotensin/vasopressin receptor AII/AVP-like; Caterpiller protein 1.1; CLR1.1; Cold autoinflammatory syndrome 1 protein; Cryopyrin; PYRIN-containing APAF1-like protein 1; NLRP3; C1orf7; CIAS1; NALP3; PYPAF1 |
| May function as an inducer of apoptosis. Interacts selectively with ASC and this complex may function as an upstream activator of NF-kappa-B signaling. Inhibits TNF-alpha induced activation and nuclear translocation of RELA/NF-KB p65. Also inhibits transcriptional activity of RELA. Activates caspase-1 in response to a number of triggers including bacterial or viral infection which leads to processing and release of IL1B and IL18. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz